Houston company's sustainable oil product reaches milestone production capacity 5 years early

overachieving

Thanks to technology advancements, Cemvita is now capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. Photo via cemvita.com

Houston-based biotech company Cemvita has achieved a key production goal five years ahead of schedule.

Thanks to technology advancements, Cemvita is now capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita has quadrupled output at the Houston plant. The company had planned to reach this milestone in 2029.

Cemvita, founded in 2017, says this achievement paves the way for increased production capacity, improved operational efficiency, and an elevated advantage in the sustainable oil market.

“What’s so amazing about synthetic biology is that humans are just scratching the surface of what’s possible,” says Moji Karimi, co-founder and CEO of Cemvita. “Our focus on the first principles has allowed us to design and create new biotech more cheaply and faster than ever before.”

The production achievement follows Cemvita’s recent breakthrough in development of a solvent-free extraction bioprocess.

In 2023, United Airlines agreed to buy up to one billion gallons of sustainable aviation fuel from Cemvita’s first full-scale plant over the course of 20 years.

Cemvita’s investors include the UAV Sustainable Flight Fund, an investment arm of Chicago-based United; Oxy Low Carbon Ventures, an investment arm of Houston-based energy company Occidental Petroleum; and Japanese equipment and machinery manufacturer Mitsubishi Heavy Industries.

From Your Site Articles

Nádia Skorupa Parachin joined Cemvita as vice president of industrial biotechnology. Photo courtesy of Cemvita

Houston biotech company expands leadership as it commercializes sustainable products

joining the team

Houston-based biotech company Cemvita recently tapped two executives to help commercialize its sustainable fuel made from carbon waste.

Nádia Skorupa Parachin came aboard as vice president of industrial biotechnology, and Phil Garcia was promoted to vice president of commercialization.

Parachin most recently oversaw several projects at Boston-based biotech company Ginkjo Bioworks. She previously co-founded Brazilian biotech startup Integra Bioprocessos.

Parachin will lead the Cemvita team that’s developing technology for production of bio-manufactured oil.

“It’s a fantastic moment, as we’re poised to take our prototyping to the next level, and all under the innovative direction of our co-founder Tara Karimi,” Parachin says in a news release. “We will be bringing something truly remarkable to market and ensuring it’s cost-effective.”

Moji Karimi, co-founder and CEO of Cemvita, says the hiring of Parachin represents “the natural next step” toward commercializing the startup’s carbon-to-oil process.

“Her background prepared her to bring the best out of the scientists at the inflection point of commercialization — really bringing things to life,” says Moji Karimi, Tara’s brother.

Parachin joins Garcia on Cemvita’s executive team.

Before being promoted to vice president of commercialization, Garcia was the startup’s commercial director and business development manager. He has a background in engineering and business development.

Founded in 2017, Cemvita recently announced a breakthrough that enables production of large quantities of oil derived from carbon waste.

In 2023, United Airlines agreed to buy up to one billion gallons of sustainable aviation fuel from Cemvita’s first full-scale plant over the course of 20 years.

------

This article originally ran on EnergyCapital.

Cemvita reported a successful pilot program on its gold hydrogen project in the Permian Basin. Photo courtesy of Cemvita

Houston cleantech company sees shining success with gold hydrogen

bling, bling

Houston-based cleantech startup Cemvita Factory is kicking things into high gear with its Gold Hydrogen product.

After successfully completing a pilot test of Gold Hydrogen in the oil-rich Permian Basin of West Texas, Cemvita has raised an undisclosed amount of funding through its new Gold H2 LLC spin-out. The lead investors are Georgia-based equipment manufacturer Chart Industries and 8090 Industries, an investment consortium with offices in New York City and Los Angeles.

Gold Hydrogen provides carbon-neutral hydrogen obtained from depleted oil and gas wells. This is achieved through bioengineering subsurface microbes in the wells to consume carbon and generate clean hydrogen.

Cemvita says it set up Gold H2 to commercialize the business via licensing, joint ventures, and outright ownership of hydrogen assets.

“We have incredible conviction in next-generation clean hydrogen production methods that leverage the vast and sprawling existing infrastructure and know-how of the oil and gas industry,” Rayyan Islam, co-founder and general partner of 8090 Industries, says in a news release.

Traditional methods of producing hydrogen without greenhouse gas emissions include electrolysis powered by renewable sources like wind, solar or water, according to Cemvita. However, production of green hydrogen through normal avenues eats up a lot of energy and money, the startup says.

By contrast, Cemvita relies on depleted oil and gas wells to cheaply produce carbon-free hydrogen.

“The commercialization and economics of the hydrogen economy will require technologies that produce the hydrogen molecule at a meaningful scale with no carbon emissions. Gold H2 is leading the charge … ,” says Jill Evanko, president and CEO of Chart Industries.

Investors in Cemvita include Oxy Low Carbon Ventures, an investment arm of Houston-based Occidental Petroleum, as well as BHP Group, Mitsubishi, and United Airlines Ventures.

Oxy Low Carbon Ventures and United Airlines Ventures are financing Cemvita’s work on sustainable jet fuel. United Airlines operates a hub at George Bush Intercontinental Airport Houston.

Founded by brother-and-sister team Moji and Tara Karimi in 2017, Cemvita uses synthetic biology to turn carbon dioxide into chemicals and alternative fuels.

The United and Occidental investment arms are planning to form a joint venture to commercialize the technology. Photo courtesy of Cemvita

Houston biotech startup scores $5M to fuel sustainable aviation innovation

seeing green

Houston cleantech startup Cemvita Factory has scored a $5 million investment from United Airlines Ventures, the venture capital fund of the Chicago-based airline.

The equity investment is aimed at propelling commercialization of sustainable aviation fuel through a process involving carbon dioxide (CO2) and synthetic microbes.

Oxy Low Carbon Ventures, a subsidiary of Houston-based Occidental Petroleum that’s a founding investor in Cemvita, and United Airlines Ventures are financing the startup’s work on sustainable jet fuel. United Airlines operates a hub at George Bush Intercontinental/Houston Airport.

If that work pans out, the United and Occidental investment arms plan to form a joint venture to commercialize the technology. The joint venture might include construction of plants for the production of sustainable aviation fuel.

Sustainable aviation fuel, known as SAF, is an alternative to jet fuel that uses non-petroleum feedstock and offers lower greenhouse gas emissions.

Founded by brother-sister team Moji and Tara Karimi in 2017, Cemvita Factory relies on synthetic biology to turn carbon dioxide into chemicals and alternative fuels, including SAF. The startup, founded in 2017, is among the first companies to employ this technology to support heavy-industry decarbonization and find ways to take advantage of microbiology to convert CO2 into fuel.

“The use of SAF is a promising approach that we believe can significantly reduce global emissions from aviation and further decarbonization initiatives to combat climate change,” Richard Jackson, president of operations for U.S. onshore resources and carbon management at Occidental, says in a news release.

Cemvita is the third SAF-related startup to receive an investment from United Airlines Ventures.

The partnership among Cemvita, Occidental, and United is among many initiatives seeking to ramp up production of SAF. For instance, the U.S. Department of Energy is collaborating with the U.S. Department of Transportation, the U.S. Department of Agriculture, and other federal agencies to develop a strategy for scaling SAF technology.

The global SAF market is projected to grow from $219 million in 2021 to more than $15.7 billion by 2030, according to Research and Markets.

The International Air Transport Association says more than 370,000 flights have been fueled by SAF since 2016. Over 26.4 million gallons of SAF were produced last year.

Last month in France, aircraft manufacturer Airbus flew a A380 test jet for about three hours with one of the four engines operating solely on SAF. The three other engines ran on conventional fuel.

In December 2021, United flew a 737 MAX 8 jet from Chicago O’Hare International Airport to Washington Reagan National Airport outside Washington, D.C., with one of the two engines operating only on SAF. It was the first commercial flight with passengers aboard to use SAF in that capacity. The other engine ran on conventional fuel.

United CEO Scott Kirby, who was aboard the historic flight, said the flight was “not only a significant milestone for efforts to decarbonize our industry, but when combined with the surge in industry commitments to produce and purchase alternative fuels, we’re demonstrating the scalable and impactful way companies can join together and play a role in addressing the biggest challenge of our lifetimes.”

For now, airlines are allowed to use up SAF for up to 50 percent of the fuel on commercial flights.

The brother-sister team at Houston-based Cemvita Factory is celebrating its series A initial closing. Photo courtesy of Cemvita

Houston-based carbon negative biotech startup closes series A round

money moves

A promising Houston startup using biotechnology to reduce carbon emissions is celebrating the initial closing of its series A fundraising round.

Cemvita Factory announced the news of its round closing, but didn't disclose the amount raised. 8090 Partners, a new investment group of entrepreneurs turned investors, led the round. Existing investor Oxy Low Carbon Ventures also contributed, along with Seldor Capital, Climate Capital, and others.

Founded by brother-sister team Moji and Tara Karimi in 2017, the company's technology biomimics photosynthesis to take carbon dioxide and turn it into something else. Cemvita uses this synthetic biology to decarbonize heavy industry across chemical manufacturing, mining, and oil and gas.

"Decarbonizing heavy industry is one of the most critical challenges in addressing climate change," says Moji Karimi, who serves as CEO, in a news release. "Synthetic biology is now primed to revolutionize heavy industries because of its inherent low-carbon advantages, and Cemvita is taking the lead in identifying and derisking the key applications."

Cemvita is currently working. with a number of clients — including Oxy, which announced its pilot in April — to reduce their carbon footprints.

"We believe the adoption rate and market size growth of our target applications will only accelerate due to the urgency for a low-carbon energy transition," Karimi continues. "The future of manufacturing will be low-carbon biomanufacturing and the future of mining will be sustainable biomining."

According to the release, the fresh funds will go toward launching Cemvita's bio-hydrogen solution, as well as to support construction and operation of a bio-ethylene pilot plant with Oxy. The pilot project, which reported success in the lab, is expected to scale.

"While synthetic biology has proven to be effective in re-imagining food and proteins, we've long held a firm belief in synthetic biology's promise in the heavy industrial space, but have waited until we've seen the right technology and team to drive real innovation in the sector," says Rayyan Islam, partner at 8090 Partners, in the release. "Cemvita's technology is a fundamental game-changer that provides a real economic solution and major players across heavy industry have taken serious notice."

It's not just investors and industrial players who have taken notice. Cemvita won the recent GS Beyond Energy Innovation Challenge from Cleantech.org. The company was also selected as a cohort member at Carbon2Value Initiative.

"Cemvita's technology is truly revolutionary in its use of CO2 and as a resource to provide viable economic solutions as more and more companies seek ways to reduce their carbon footprint. We remain impressed and excited about Cemvita's technology's positive impact on Earth and beyond," says Sidney N. Nakahodo, founder and general partner of Seldor Capital, in the release.

Cemvita Factory is working on a pilot plant with Oxy to scale its biotechnology. Photo via OxyLowCarbon.com

Oxy taps Houston startup's carbon negative biotechnology for new pilot plant

sustainability moves

Occidental's venture arm — Oxy Low Carbon Ventures — has announced its plans to construct and operate a one metric ton per month bio-ethylene pilot plant featuring Houston-based Cemvita Factory's technology that biomimics photosynthesis to convert carbon dioxide into feedstocks.

The new plant will scale the process, which was jointly developed between Cemvita and OLCV, and is expected sometime next year, according to a press release from Oxy.

"Today bio-ethylene is made from bio-ethanol, which is made from sugarcane, which in turn was created by photosynthesizing CO2. Our bio-synthetic process simply requires CO2, water and light to produce bio-ethylene, and that's why it saves a lot of cost and carbon emissions," says Moji Karimi, co-founder and CEO of Cemvita Factory, in the release. "This project is a great example of how Cemvita is applying industrial-strength synthetic biology to help our clients lower their carbon footprint while creating new revenue streams."

Oxy and Cemvita have been working together for a while, and in 2019, OLCV invested an undisclosed amount into the startup. The investment, according to the release, was made to jointly explore how these advances in synthetic biology can be used for sustainability efforts in the bio-manufacturing of OxyChem's products.

"This technology could provide an opportunity to offer a new, non-hydrocarbon-sourced ethylene product to the market, reducing carbon emissions, and in the future benefit our affiliate, OxyChem, which is a large producer and consumer of ethylene in its chlorovinyls business," says Robert Zeller, vice president of technology at OLCV, in a news release.

Moji Karimi founded the company with his sister and Cemvita CTO, Tara, in 2017. The idea was to biomimic photosynthesis to take CO2 and turn it into something else. The first iteration of the technology turned CO2 into sugar — the classic photosynthesis process. Karimi says the idea was to create this process for space, so that astronauts can turn the CO2 they breathe out into a calorie source.

"Nature provided the inspiration," noted Dr. Tara Karimi, co-founder and CTO of Cemvita Factory. "We took a gene from a banana and genetically engineered it into our CO2-utilizing host microorganism. We are now significantly increasing its productivity with the goal to achieve commercial metrics that we have defined alongside OLCV."

A couple weeks ago, Moji Karimi joined the Houston Innovators Podcast to discuss growth and challenges Cemvita Factory faced.

"We're defining this new category for application of synthetic biology in heavy industries for decarbonization," he shares on the show. Stream the episode below.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

2024 Google search volume for terms related to investing
Number of investors
Number of businesses receiving investments in 2024
Total amount of capital invested in businesses in 2024
Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME